VRPX Virpax Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: VRPX

Price (delayed)

$0.849

Market cap

$4.15M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$13.47

Enterprise value

$2.28M

Virpax is developing branded, non-addictive pain management products candidates using its proprietary technologies to optimize and target drug delivery. Virpax is initially seeking FDA approval using its three patented drug ...

Highlights
The EPS has grown by 6% from the previous quarter but it has contracted by 3.2% YoY
The equity has plunged by 130% from the previous quarter and by 123% YoY
Virpax Pharmaceuticals's quick ratio has plunged by 91% YoY and by 19% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://virpaxpharma.com
Peers: OLMA OMER OMGA ONCT

Key stats

What are the main financial stats of VRPX
Market
Shares outstanding
4.89M
Market cap
$4.15M
Enterprise value
$2.28M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$17.22M
EBITDA
-$17.22M
Free cash flow
-$15.04M
Per share
EPS
-$13.47
Free cash flow per share
-$7.6
Book value per share
-$2.39
Revenue per share
$0
TBVPS
$1.31
Balance sheet
Total assets
$2.59M
Total liabilities
$5.39M
Debt
$0
Equity
-$2.79M
Working capital
-$2.79M
Liquidity
Debt to equity
0
Current ratio
0.48
Quick ratio
0.35
Net debt/EBITDA
0.11
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-242.7%
Return on equity
-1,554.7%
Return on invested capital
N/A
Return on capital employed
N/A
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

VRPX stock price

How has the Virpax Pharmaceuticals stock price performed over time
Intraday
6.13%
1 week
4.81%
1 month
-18.37%
1 year
-89.56%
YTD
-73.47%
QTD
64.12%

Financial performance

How have Virpax Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$17.56M
Net income
-$17.23M
Gross margin
N/A
Net margin
N/A
Virpax Pharmaceuticals's net income has decreased by 13% YoY
VRPX's operating income is down by 12% year-on-year

Growth

What is Virpax Pharmaceuticals's growth rate over time

Valuation

What is Virpax Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 6% from the previous quarter but it has contracted by 3.2% YoY
The equity has plunged by 130% from the previous quarter and by 123% YoY

Efficiency

How efficient is Virpax Pharmaceuticals business performance
The ROA has plunged by 50% from the previous quarter

Dividends

What is VRPX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VRPX.

Financial health

How did Virpax Pharmaceuticals financials performed over time
The total assets is 52% less than the total liabilities
Virpax Pharmaceuticals's quick ratio has plunged by 91% YoY and by 19% from the previous quarter
VRPX's current ratio has dropped by 89% year-on-year and by 33% since the previous quarter
Virpax Pharmaceuticals's debt is 100% more than its equity
The equity has plunged by 130% from the previous quarter and by 123% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.